Old Web
English
Sign In
Acemap
>
authorDetail
>
Martin Sanabria
Martin Sanabria
Bayer
Medicine
Patient portal
Emergency medicine
Pediatrics
Haemophilia A
4
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A.
2021
BMJ Open
Martin Sanabria
María Teresa Álvarez-Román
Giancarlo Castaman
Maissaa Janbain
Tadashi Matsushita
Karina Meijer
Johannes Oldenburg
Sabine Friedl
Mark T. Reding
Show All
Source
Cite
Save
Citations (0)
First interim analysis from the observational hempowr study evaluating effectiveness and safety of real-world treatment with damoctocog alfa pegol in previously treated patients with hemophilia a
2021
Mark T. Reding
M. Teresa Alvarez-Roman
Martin Sanabria
Giancarlo Castaman
Maissaa Janbain
Tadashi Matsushita
Karina Meijer
K. S. Schmidt
Johannes Oldenburg
Show All
Source
Cite
Save
Citations (0)
Adherence to prophylaxis in adult patients with severe haemophilia A.
2020
Haemophilia
Santiago Bonanad
M. García-Dasí
José A. Aznar
María Eva Mingot-Castellano
Victor Jiménez Yuste
MªVictoria Calle
Antonio Palma
María Fernanda López-Fernández
Pascual Marco
Maria José Paloma
Nuria Fernandez-Mosteirin
Bernat Galmes
Martin Sanabria
MªPilar Álvarez
Show All
Source
Cite
Save
Citations (1)
Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study
2019
Blood
Johannes Oldenburg
María Teresa Álvarez-Román
Giancarlo Castaman
Maissaa Janbain
Tadashi Matsushita
Karina Meijer
Sabine Friedl
Martin Sanabria
Mark T. Reding
Show All
Source
Cite
Save
Citations (1)
1